Katherine Chinchilla1,2, Cristiano Matos3, Victoria Hall1, Florence van Hunsel4. 1. Centro Nacional de Información de Medicamentos, Instituto de Investigaciones Farmacéuticas, Facultad de Farmacia, Universidad de Costa Rica, San José, Costa Rica. 2. Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, 's-Hertogenbosch, The Netherlands. 3. Instituto Politécnico De Coimbra, ESTESC-Coimbra Health School, Farmácia, Coimbra, Portugal. 4. Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, 's-Hertogenbosch, The Netherlands. f.vanhunsel@lareb.nl.
Abstract
INTRODUCTION: European drug regulations aim for a patient-centered approach, including involving patients in the pharmacovigilance (PV) systems. However many patient organizations have little experience on how they can participate in PV activities. AIM: The aim of this study was to understand patient organizations' perceptions of PV, the barriers they face when implementing PV activities, and their interaction with other stakeholders and suggest methods for the stimulation of patient organizations as promoters of PV. METHODS: A sequential qualitative method study was conducted and integrated with the quantitative study performed by Matos, Weits, and van Hunsel to complete a mixed method study. RESULTS: The qualitative phase expands the understanding of the quantitative results from a previous study by broadening the knowledge on external barriers and internal barriers that patient organizations face when implementing PV activities. The strategies to stimulate patient-organization participation are the creation of more awareness campaigns, more research that creates awareness, education for patient organizations, communication of real PV examples, creation of a targeted PV system, creation of a PV communication network that provides feedback to patients, improvement of understanding of all stakeholders, and a more proactive approach from national competent authorities. CONCLUSION: Both study phases show congruent results regarding patients' involvement and the activities patient organizations perform to promote drug safety. Patient organizations progressively position themselves as stakeholders in PV, carrying out many activities that stimulate awareness and participation of their members in drug safety, but still face internal and external barriers that can hamper their involvement.
INTRODUCTION: European drug regulations aim for a patient-centered approach, including involving patients in the pharmacovigilance (PV) systems. However many patient organizations have little experience on how they can participate in PV activities. AIM: The aim of this study was to understand patient organizations' perceptions of PV, the barriers they face when implementing PV activities, and their interaction with other stakeholders and suggest methods for the stimulation of patient organizations as promoters of PV. METHODS: A sequential qualitative method study was conducted and integrated with the quantitative study performed by Matos, Weits, and van Hunsel to complete a mixed method study. RESULTS: The qualitative phase expands the understanding of the quantitative results from a previous study by broadening the knowledge on external barriers and internal barriers that patient organizations face when implementing PV activities. The strategies to stimulate patient-organization participation are the creation of more awareness campaigns, more research that creates awareness, education for patient organizations, communication of real PV examples, creation of a targeted PV system, creation of a PV communication network that provides feedback to patients, improvement of understanding of all stakeholders, and a more proactive approach from national competent authorities. CONCLUSION: Both study phases show congruent results regarding patients' involvement and the activities patient organizations perform to promote drug safety. Patient organizations progressively position themselves as stakeholders in PV, carrying out many activities that stimulate awareness and participation of their members in drug safety, but still face internal and external barriers that can hamper their involvement.
Authors: Jean Lester; George A Neyarapally; Earlene Lipowski; Cheryl Fossum Graham; Marni Hall; Gerald Dal Pan Journal: Pharmacoepidemiol Drug Saf Date: 2013-01-02 Impact factor: 2.890
Authors: José A Sacristán; Alfonso Aguarón; Cristina Avendaño-Solá; Pilar Garrido; Juan Carrión; Alipio Gutiérrez; Robert Kroes; Angeles Flores Journal: Patient Prefer Adherence Date: 2016-04-27 Impact factor: 2.711
Authors: Anton Berns; Ulrik Ringborg; Alexander Eggermont; Michael Baumann; Fabien Calvo; Angelika Eggert; Carolina Espina; Douglas Hanahan; Denis Lacombe; Francesco de Lorenzo; Simon Oberst; Thierry Philip; Joachim Schüz; Josep Tabernero; Julio E Celis Journal: Mol Oncol Date: 2019-11 Impact factor: 6.603
Authors: Luís Monteiro; Matilde Monteiro-Soares; Cristiano Matos; Inês Ribeiro-Vaz; Andreia Teixeira; Carlos Martins Journal: Int J Environ Res Public Health Date: 2022-06-04 Impact factor: 4.614
Authors: Monica van Hoof; Katherine Chinchilla; Linda Härmark; Cristiano Matos; Pedro Inácio; Florence van Hunsel Journal: Drug Saf Date: 2022-08-25 Impact factor: 5.228